期刊
SCIENTIFIC REPORTS
卷 10, 期 1, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-020-70924-z
关键词
-
资金
- Ross Trust
- Translational Cancer Research Network (TCRN)
- National Health and Medical Research Council (NHMRC) of Australia [APP339435]
- Cancer Council Queensland [4196615]
- Cancer Council Tasmania [403031, 457636]
- Cancer Australia Priority-driven Collaborative Cancer Research Scheme [552468]
- Cancer Australia [1010859]
- Royal Brisbane and Women's Hospital Foundation
- Queensland Institute of Medical Research
- National Health and Medical Research Council (NHMRC) Early Career Fellowship [APP1111246]
- NHMRC Senior Research Fellowship [APP1061779]
- NSW: John Hunter Hospital
- NSW: Mater Misericordiae Hospital (Newcastle)
- NSW: Newcastle Private Hospital
- NSW: North Shore Private Hospital
- NSW: Royal Hospital for Women
- NSW: Royal Prince Alfred Hospital
- NSW: Royal North Shore Hospital
- NSW: St George Hospital
- NSW: Westmead Hospital
- NSW: Westmead Private Hospital
- QLD: Brisbane Private Hospital
- QLD: Greenslopes Hospital
- QLD: Mater Misericordiae Hospitals
- QLD: Royal Brisbane and Women's Hospital
- QLD: Wesley Hospital
- QLD: Queensland Cancer Registry
- SA: Adelaide Pathology Partners
- SA: Burnside Hospital
- SA: Calvary Hospital
- SA: Flinders Medical Centre
- SA: Queen Elizabeth Hospital
- SA: Royal Adelaide Hospital
- SA: South Australian Cancer Registry
- TAS: Launceston Hospital
- TAS: North West Regional Hospitals
- TAS: Royal Hobart Hospital
- VIC: Freemasons Hospital
- VIC: Melbourne Pathology Services
- VIC: Mercy Hospital for Women
- VIC: Royal Women's Hospital
- VIC: Victorian Cancer Registry
- WA: King Edward Memorial Hospital
- WA: St John of God Hospital Subiaco
- WA: St John of God Hospital Murdoch
- WA: Western Australian Cancer Registry
- NSW: Liverpool Hospital
- NSW: Mater Misericordiae Hospital (Sydney)
ROR1 and ROR2 are receptor tyrosine kinases with altered expression in a range of cancers. Silencing ROR1 or ROR2 in different tumour types has been shown to inhibit proliferation and decrease metastatic potential. The aim of this study was to investigate the role of ROR1 and ROR2 in endometrial cancer via immunohistochemistry (IHC) in a large endometrial cancer patient cohort (n=499) and through in vitro analysis in endometrial cancer cell lines. Correlation was assessed between ROR1/2 expression and clinicopathological parameters. Kaplan Meier curves were produced for 5-year progression free survival (PFS) and overall survival (OS) with low/moderate versus high ROR1/2 intensity. Cox multivariate regression was applied to analyse the effect of selected covariates on the PFS and OS. The effect of ROR1 and/or ROR2 modulation on cell proliferation, adhesion, migration and invasion was analysed in two endometrial cancer cell lines (KLE and MFE-296). We observed a significant decrease in OS and PFS in patients with high ROR1 expression. ROR1 silencing and ROR2 overexpression significantly inhibited proliferation of KLE endometrial cancer cells and decreased migration. This study supports the oncogenic role of ROR1 in endometrial cancer, and warrants investigation of future application of ROR1-targeting therapies in endometrial cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据